Record Display for the EPA National Library Catalog


Main Title Support document, decision not to require testing for health effects : acrylamide /
CORP Author United States. Environmental Protection Agency. Office of Toxic Substances. Assessment Division.
Publisher U.S. Environmental Protection Agency, Office of Pesticides and Toxic Substances,
Year Published 1980
Report Number EPA 560/11-80-016
Stock Number PB80-220312
OCLC Number 08453100
Subjects Acrylamides--toxicity ; Acrylamide--Toxicology ; Hazardous substances
Additional Subjects Acrylamide--Toxicology ; Hazardous substances ; Physiological effects ; Recommendations ; Assessments ; Laboratory animals ; Nervous system ; Signs and symptoms ; Testing ; Exposure ; Toxic substances ; Acrylamides ; Toxic Substances Control Act ; Public Law 94-469 ; Neurotoxins
Internet Access
Description Access URL
Library Call Number Additional Info Location Last
EJAD  EPA 560/11-80-016 Region 3 Library/Philadelphia, PA 03/20/1992 DISPERSAL
EJBD ARCHIVE EPA 560-11-80-016 Headquarters Library/Washington,DC 01/18/2011
EJED  EPA 560/11-80-016 OCSPP Chemical Library/Washington,DC 01/01/1988
ERAD  EPA 560/11-80-016 Region 9 Library/San Francisco,CA 09/04/2012
ESAD  EPA 560-11-80-016 Region 10 Library/Seattle,WA 09/10/2004
NTIS  PB80-220312 Some EPA libraries have a fiche copy filed under the call number shown. 07/26/2022
Collation 33 p.
It has been found that acrylamide is neurotoxic, producing central-peripheral axonopathies. The animal species in which this effect was demonstrated include rats, mice, cats, dogs, baboons, and monkeys. In addition, there are at least 48 published cases of the occupational toxicity and 5 cases of the nonoccupational toxicity of acrylamide to humans, many of whom manifested a measurable degree of neurotoxicity (central-peripheral axonopathy). In humans, the predominant signs of neurotoxicity are related to peripheral nerve involvement and, to a lesser extent, central nervous system involvement. A variety of other signs and symptoms also are generally reported, the most common ones occurring in the skin, hands, and feet. The onset of effects may be reversible, although this is not always the case. Based on laboratory data, EPA has concluded that acrylamide is a potent neurotoxicant at very low levels. This conclusion has been substantiated by a 1-year (oral administration) study in cats indicating a no-effect level of 0.3-1.0 mg/kg/day. EPA does not plan to require the health effects testing recommended by the Interagency Testing Committee. Instead, EPA plans to evaluate acrylamide for possible regulatory controls.
Cover title: Assessment of testing needs : acrylamide : support document for decision not to require testing for health effects, Toxic Substances Control Act, Section 4. "EPA-560/11-80-016." "June 1980."